IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Innate Pharma SA
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026
$1.46+0.03 (+2.10%)
Close on Oct 19, 2026
Share price
−$0.69 (−32.09%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Innate Pharma SA saw revenue fall 55.2% to €9.01M over fiscal 2025. Free cash flow was -€52.90M.
Revenue
€9.01M
-55.2% vs. a year earlier
Operating income
-€54.01M
FY2025
Free cash flow
-€52.90M
FY2025
EPS, diluted
-0.55 EUR
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- €9.01M
- EPS, diluted
- -0.55 EUR
- Free cash flow
- -€52.90M
Valuation needs the share price. It fills in once daily prices are connected and converted from EUR.
Ten years at a glance
Fiscal years 2016 to 2025, EUR
Revenue
€9.01M-55.2% YoY
Operating income
-€54.01M
EPS, diluted
-0.55 EUR
Free cash flow
-€52.90M
Reported period